Longitudinal nonlinear mixed effects modeling of <scp>EGFR</scp> mutations in <scp>ctDNA</scp> as predictor of disease progression in treatment of <scp>EGFR</scp> ‐mutant non‐small cell lung cancer-Reference-Cited by-同舟云学术

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR ‐mutant non‐small cell lung cancer

Published:2022-06-30 Issue:8 Volume:15 Page:1916-1925
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Janssen Julie M.¹,Verheijen Remy B.¹,van Duijl Tirsa T.¹,Lin Lishi¹^ORCID,van den Heuvel Michel M.²³,Beijnen Jos H.¹⁴,Steeghs Neeltje⁵,van den Broek Daan⁶,Huitema Alwin D. R.¹⁷,Dorlo Thomas P. C.¹^ORCID

Affiliation:

1. Department of Pharmacy & Pharmacology The Netherlands Cancer Institute ‐ Antoni van Leeuwenhoek Amsterdam The Netherlands

2. Department of Respiratory Disease Radboud University Medical Centre Nijmegen The Netherlands

3. Department of Thoracic Oncology The Netherlands Cancer Institute ‐ Antoni van Leeuwenhoek Amsterdam The Netherlands

4. Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands

5. Department of Medical Oncology and Clinical Pharmacology The Netherlands Cancer Institute ‐ Antoni van Leeuwenhoek Amsterdam The Netherlands

6. Department of Laboratory Medicine The Netherlands Cancer Institute ‐ Antoni van Leeuwenhoek Amsterdam The Netherlands

7. Department of Clinical Pharmacy, University Medical Center Utrecht Utrecht University Utrecht The Netherlands

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13300

Reference34 articles.

1. Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

2. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

3. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

4. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study

5. EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer;Clinical Pharmacology & Therapeutics;2024-08-12

2. Moving the needle for oncology dose optimization: A call for action;Clinical and Translational Science;2024-06

3. Moving the needle for oncology dose optimization: A call for action;CPT: Pharmacometrics & Systems Pharmacology;2024-05-22

4. Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper;Clinical Pharmacology & Therapeutics;2024-05-16

5. Moving the Needle for Oncology Dose Optimization: A Call for Action;Clinical Pharmacology & Therapeutics;2024-05-12